SAN DIEGO, CA / ACCESSWIRE / September 11, 2019 / The Shareholders Foundation, Inc. announces that a lawsuit is pending on behalf of certain consumers related to various drugs from Gilead Sciences, Inc used to treat HIV.
The plaintiffs allege that Gilead Sciences, Inc. (GILD) and its alleged coconspirators engaged in a long-running scheme to restrain competition with respect to some of the most important drugs used to treat HIV infection.
The plaintiffs claim that through an array of anticompetitive practices Gilead Sciences, Inc. (GILD) has acquired and maintained a monopoly in the market for drugs that comprise the modern HIV treatment regimen known as “combination cocktail” and that the scheme has enabled Gilead Sciences, Inc. (GILD) and its alleged coconspirators to unlawfully extend patent protection for their drugs, impair entry by would-be generic competitors, and charge exorbitant, supracompetitive prices for the drugs that people living with HIV need to survive.
The plaintiffs say that more than 80% of patients starting an HIV regimen in the U.S., and more than 80% of continuing patients, take one or more of Gilead Sciences, Inc’s products every day, and that Gilead Sciences, Inc’s sales of these products in the U.S. alone are more than $11 billion annually.
Those who purchased Gilead Sciences, Inc. (GILD) shares should contact the Shareholders Foundation, Inc.
Shareholders Foundation, Inc.
+1 (858) 779-1554
3111 Camino Del Rio North
San Diego, CA 92108
The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
SOURCE: Shareholders Foundation, Inc.
View source version on accesswire.com: